Affordable Access

Low expression of NTF3 is associated with unfavorable prognosis in hepatocellular carcinoma

Authors
  • Yang, Qiu-Xia1
  • Liu, Ting1
  • Yang, Jun-Ling2
  • Liu, Fang1
  • Chang, Li1
  • Che, Guang-Lu1
  • Lai, Shu-Yu1
  • Jiang, Yong-Mei1
  • 1 Department of Laboratory Medicine, West China Second University Hospital, and Key Laboratory of Obstetric & Gynecologic and Pediatric Diseases and Birth Defects of Ministry of Education, Sichuan University, Chengdu, China
  • 2 Department of Ultrasound, Chengdu Jinniu District People’s Hospital, Chengdu, China
Type
Published Article
Journal
International journal of clinical and experimental pathology
Publication Date
Sep 01, 2020
Volume
13
Issue
9
Pages
2280–2288
Identifiers
PMID: 33042332
PMCID: PMC7539881
Source
PubMed Central
Keywords
License
Unknown

Abstract

Neurotrophin 3 (NTF3) is a member of the nerve growth factor (NGF) family involved in cancer progression, including medulloblastoma and breast cancer. However, the expression and prognostic value of NTF3 has not been reported in human hepatocellular carcinoma (HCC). Here, we first performed an mRNA expression analysis of the NTF family using the TCGA database and found that NTF3 was significantly downregulated in patients with HCC. Low expression of NTF3 in various HCC cohorts from the GEO database was frequently identified. Consistently, NTF3 protein level was also decreased in HCC tissues as compared with controls. Moreover, survival analysis showed that low NTF3 expression correlated with shorter overall survival (OS) and disease-free survival (DFS) in HCC patients. In addition, there was a positive correlation between the mRNA expression of NTF3 and TrkC in HCC specimens. Generally, these results revealed that low expression of NTF3 predicted an unfavorable clinical outcome. NTF3 may be a diagnostic and prognostic marker in HCC.

Report this publication

Statistics

Seen <100 times